Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor in Cystic Fibrosis Patients Under 24 Months of Age
2015-001997-16Phase 3
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety in Part A, Pharmacokinetics in Part A and 1 more.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-001997-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001997-16.